The Drugs for Neglected Diseases initiative (DNDi) and other researchers, including MSF-Crash Dr. Jean Hervé Bradol, report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. 

Pharmaceutical companies produce drugs and are increasing involved in the clinical trials of these products. This conflict of interest is incompatible with the expectations  of Public Health. Rony Brauman suggests that the industry no longer be responsible for therapeutic trials.